Product Program year 2023 Source: CMS Open Payments

Qbrelis

Drug pediatric hypertension

NDC 52652-3001-1

Open in the dashboard

General payments

$34,294

232 payments

Research payments

$0

0 payments

Through program year 2023, $34,294 in general payments and $0 in research payments were reported against Qbrelis (pediatric hypertension).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2023 General $190 11
2022 General $374 21
2021 General $31,029 56
2020 General $1,596 87
2019 General $1,106 57

Breakdown

Who paid General payments · program years 2019–2023
  1. CutisPharma, Inc. $32,607 143 payments
  2. Silvergate Pharmaceuticals, Inc. $1,688 89 payments
Top recipients General payments · program year 2023
  1. Luke Wall Allergy & Immunology · New Orleans, LA $19 10% · 1 payment
  2. Diego Aviles Pediatric Nephrology · New Orleans, LA $19 10% · 1 payment
  3. Elizabeth Alonso Pediatric Gastroenterology · Baton Rouge, LA $19 10% · 1 payment
  4. James Krulisky Pediatric Cardiology · New Orleans, LA $19 10% · 1 payment
  5. Eric Bankert Sports Medicine · New Orleans, LA $19 10% · 1 payment

The top 5 of 11 recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Sports Medicine Pediatrics $19 10% · 1 practitioner
  2. Neurology with Special Qualifications in Child Neurology Psychiatry & Neurology $19 10% · 1 practitioner
  3. Nurse Practitioner, Acute Care Nurse Practitioner $19 10% · 1 practitioner
  4. Pediatric Nephrology Pediatrics $19 10% · 1 practitioner
  5. Allergy & Immunology $19 10% · 1 practitioner

The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. Louisiana $130 68% · 7 recipients
  2. Tennessee $31 17% · 2 recipients
  3. Nebraska $14 8% · 1 recipient
  4. Virginia $14 8% · 1 recipient

Each share is of general payments naming this product in 2023 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

291

Prescriptions dispensed, refills included

Drug cost

$534,688

Paid at the pharmacy, in all

Prescribers

22

With 11 or more claims of it

Medicare Part D drugs matched to Qbrelis, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Qbrelis Lisinopril Same name 22 291 $534,688

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 22 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Atef Mousa Internal Medicine NJ 24 $23,170 None on record
Daniel Feig Pediatric Medicine AL 23 $26,458 None on record
Peter McCauley Nephrology CA 15 $4,078 None on record
Krista Heckert Nurse Practitioner MI 13 $48,232 None on record
Sara Mixter Internal Medicine MD 13 $43,057 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 22 in the dashboard with a free account
232 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record